Patent intelligence · US
US 12338269
IL-2 superagonists in combination with anti-PD-1 antibodies
IL-2 superagonists in combination with anti-PD-1 antibodies
Patent details — US 12338269
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 24, 2025
- Expiration
- Jun 19, 2045
- Applicant
- Medicenna Therapeutics Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2039/5256, A61K2039/55533
Quick answer
US 12338269 (IL-2 superagonists in combination with anti-PD-1 antibodies) is held by Medicenna Therapeutics Inc.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Medicenna Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2039/5256, A61K2039/55533, A61K35/76, A61K38/1709
More from Medicenna Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404497
Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
granted -
US 12274735
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
granted -
US 11680090
Interleukin-2 fusion proteins and uses thereof
granted -
US 11542312
IL-2 superagonists in combination with anti-PD-1 antibodies
granted -
US 11352402
Interleukin-4 receptor-binding fusion proteins and uses thereof
granted -
US 10781242
Interleukin-2 fusion proteins and uses thereof
granted -
US 10106592
Interleukin-4 receptor-binding fusion proteins and uses thereof
granted
Frequently asked questions
What is US patent 12338269?
US 12338269 (IL-2 superagonists in combination with anti-PD-1 antibodies) is held by Medicenna Therapeutics Inc.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12338269?
Medicenna Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12338269 expire?
Our index shows an expiration date of Jun 19, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.